This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Pfizer says indirect purchasers can't yet appeal order in US EpiPen antitrust suit

( September 6, 2022, 22:31 GMT | Official Statement) -- MLex Summary: Pfizer filed a brief opposing indirect purchasers’ request for immediate appeal of a decision that dismissed their US claims that Pfizer conspired to delay generic EpiPen, saying they cannot claim any exception to the Illinois Brick doctrine. “[T]here is no ‘substantial ground for difference of opinion’ on whether the so-called ‘co-conspirator exception’ to Illinois Brick can apply to salvage their indirect purchaser claims of generic delay against Pfizer,” it said.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections